World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
84
Citations
32773
World Ranking
3261
National Ranking
1651

Overview

Peter D. Senter is affiliated with Seattle Genetics in the United States. Their research work spans various domains within medicine and biochemistry, genetics, and molecular biology, focusing primarily on oncology and molecular biology subfields. They have authored multiple publications related to cancer research, drug development, and immunology topics.

The scientist's recent papers include:

  • Antibody-drug conjugates come of age in oncology, 2023, Nature Reviews Drug Discovery
  • Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers, 2020, Molecular Cancer Therapeutics
  • Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux-positive Tumor Models, 2020, Molecular Cancer Therapeutics
  • Improving Antibody-Tubulysin Conjugates through Linker Chemistry and Site-Specific Conjugation, 2020, ChemMedChem
  • Structure-activity relationships of tubulysin analogues, 2020, Bioorganic & Medicinal Chemistry Letters

Frequent coauthors collaborating with Peter D. Senter include:

  • Jessica K. Simmons
  • Scott C. Jeffrey
  • Shyra J. Gardai
  • Kim K. Emmerton
  • Robert P. Lyon

Peter D. Senter's work has appeared predominantly in the following publication venues:

  • Cancer Research (6 publications)
  • Molecular Cancer Therapeutics (5 publications)
  • ChemMedChem (2 publications)
  • Nature Reviews Drug Discovery (1 publication)
  • Science Advances (1 publication)

The primary fields of study for this scientist are Medicine and Biochemistry, Genetics and Molecular Biology, with a notable focus on the subfields of Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Immunology, and Infectious Diseases.

Main research topics covered by Peter D. Senter include:

  • Monoclonal and Polyclonal Antibodies Research
  • HER2/EGFR in Cancer Research
  • CAR-T cell therapy research
  • Glycosylation and Glycoproteins Research
  • Cancer therapeutics and mechanisms
  • Bioactive Compounds and Antitumor Agents
  • Cancer Treatment and Pharmacology

Best Publications

  • Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

    Svetlana O Doronina;Brian E Toki;Michael Y Torgov;Brian A Mendelsohn

  • Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate

    Kevin J. Hamblett;Peter D. Senter;Dana F. Chace;Michael M. C. Sun

  • cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

    Joseph A Francisco;Charles G Cerveny;Damon L Meyer;Bruce J Mixan

  • Arming antibodies: prospects and challenges for immunoconjugates

    Anna M Wu;Peter D Senter

  • conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga

    Allen J Ebens;Brian E Toki;Mark X Sliwkowski;Paul Polakis

  • The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

    Peter D Senter;Eric L Sievers

  • Antibody-Drug Conjugates in Cancer Therapy

    Eric L Sievers;Peter D Senter

  • Antibody–drug conjugates: targeted drug delivery for cancer

    Stephen C Alley;Nicole M Okeley;Peter D Senter

  • Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity

    Svetlana O. Doronina;Brian A. Mendelsohn;Tim D. Bovee;Charles G. Cerveny

  • Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells

    Peter D. Senter;Mark G. Saulnier;Joseph P. Brown;David E. Kerr

  • Contribution of linker stability to the activities of anticancer immunoconjugates.

    Stephen C. Alley;Dennis R. Benjamin;Scott C. Jeffrey;Nicole M. Okeley

  • Lægemiddelkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektionssygdom

    Senter Peter D;Doronina Svetlana;Toki Brian E

  • Potent antibody drug conjugates for cancer therapy.

    Peter D Senter

  • Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index.

    Robert P Lyon;Tim D Bovee;Svetlana O Doronina;Patrick J Burke

  • SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

    May S. Kung Sutherland;Roland B. Walter;Scott C. Jeffrey;Patrick J. Burke

  • Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides

    Michael M. C. Sun;Kevin S. Beam;Charles G. Cerveny;Kevin J. Hamblett

  • Efficient Cancer Therapy with a Nanobody-Based Conjugate

    Virna Cortez-Retamozo;Natalija Backmann;Peter D. Senter;Ullrich Wernery

  • Antibody-drug conjugates for cancer therapy.

    Paul J. Carter;Peter D. Senter

  • Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.

    Nicole M Okeley;Jamie B Miyamoto;Xinqun Zhang;Russell J Sanderson

  • In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate

    Russell J. Sanderson;Michelle A. Hering;Stephanie F. James;Michael M.C. Sun

Frequent Co-Authors

Peter S. Linsley
Peter S. Linsley Benaroya Research Institute
Paul Polakis
Paul Polakis Genentech
Karl Erik Hellström
Karl Erik Hellström University of Washington
Ingegerd Hellström
Ingegerd Hellström University of Washington
John M. Lambert
John M. Lambert ImmunoGen (United States)
Paul J. Maddon
Paul J. Maddon Columbia University
Irwin D. Bernstein
Irwin D. Bernstein Fred Hutchinson Cancer Research Center
Robert M. Coates
Robert M. Coates University of Illinois at Urbana-Champaign
Herren Wu
Herren Wu AstraZeneca (United Kingdom)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Expanding your expertise in Biology and Biochemistry can open doors to a wide range of healthcare and science-related careers. Many students pursue advanced education through flexible online programs tailored to fit diverse professional goals and schedules.

For those interested in advanced nursing leadership, several online dnp programs without clinicals are available, eliminating the need for on-site practice while still delivering rigorous educational content. Alternatively, management-focused programs such as a doctorate in healthcare management prepare graduates for high-level administrative roles across hospitals and clinics.

If your interests lean toward pharmacological sciences, an online pharmacy school can help you achieve the qualifications needed to become a licensed pharmacist or researcher. Additionally, those looking to combine a passion for health and human performance may consider earning an exercise science degree online accredited by recognized bodies, which opens up careers in clinical settings, wellness coaching, and sports medicine.

Best Scientists Citing Peter D. Senter

Trending Scientists

Recently Published Articles